SJS Investment Consulting’s Pacira BioSciences PCRX Stock Holding History

SJS Investment Consulting’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.75K	Buy	+148	New	+$3.5K	﹤0.01%	1500
2024 Q3	–	Sell	-5	Closed	-$144	–	1700
2024 Q2	$144	Hold	5	–	–	﹤0.01%	1554
2024 Q1	$147	Hold	5	–	–	﹤0.01%	1531
2023 Q4	$169	Buy	5 +1	+25%	+$29	﹤0.01%	1491
2023 Q3	$123	Sell	4 -1	-20%	-$36	﹤0.01%	1519
2023 Q2	$201	Sell	5 -1	-17%	-$41	﹤0.01%	1406
2023 Q1	$245	Buy	6 +1	+20%	+$40	﹤0.01%	1319
2022 Q4	$193	Buy	5 +1	+25%	+$49	﹤0.01%	1419
2022 Q3	$0	Buy	+4	New	+$222	﹤0.01%	1416
2022 Q1	$12K	Buy	163 +1	+0.6%	+$67	﹤0.01%	371
2021 Q4	$10K	Buy	+162	New	+$8.93K	﹤0.01%	375

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's PCRX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 148 shares worth $3.75K. The stake represents ﹤0.01% of the portfolio and ranks #1500 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in PCRX as recently as Q2 2024.

SJS Investment Consulting first reported a position in PCRX in Q4 2021 and has held it in 11 quarters since. The position peaked at $12K in Q1 2022. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

SJS Investment Consulting held 148 shares of Pacira BioSciences worth $3.75K as of Q2 2026.
Pacira BioSciences was a new SJS Investment Consulting position in Q2 2026.
Pacira BioSciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1500 holding.
SJS Investment Consulting first reported a position in Pacira BioSciences in Q4 2021 and has held it in 11 quarters since.
SJS Investment Consulting's Pacira BioSciences position peaked at $12K in Q1 2022.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.